AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Interleukin-23 receptor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q5VWK5

UPID:

IL23R_HUMAN

Alternative names:

-

Alternative UPACC:

Q5VWK5; C9JGX4; Q4VGP1; Q4VGP2; Q4VGP3; Q4VGP4; Q4VGP5; Q4VGP6; Q5VWK7; Q8IW84; Q8NFQ9; Q96AS1

Background:

The Interleukin-23 receptor, encoded by the gene with accession number Q5VWK5, plays a pivotal role in the immune system. It forms a complex with IL12RB1 to bind IL23, initiating the Jak-Stat signaling cascade. This process is crucial for the stimulation of T-cells, NK cells, and certain macrophage/myeloid cells, contributing to both innate and adaptive immunity. Its involvement in the body's acute response to peripheral tissue infections underscores its significance.

Therapeutic significance:

Given its central role in mediating immune responses, the Interleukin-23 receptor is implicated in Inflammatory bowel disease 17, encompassing Crohn's disease and ulcerative colitis. These conditions are characterized by chronic inflammation of the gastrointestinal tract. Understanding the receptor's function could lead to novel therapeutic strategies targeting these autoimmune inflammatory diseases, potentially offering new hope for patients.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.